ProfileGDS4814 / ILMN_1840286
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 14% 11% 55% 27% 20% 9% 3% 12% 28% 15% 46% 18% 5% 21% 9% 14% 48% 24% 44% 11% 18% 15% 11% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)42.21314
GSM780708Untreated after 4 days (C2_1)41.351811
GSM780709Untreated after 4 days (C3_1)52.424655
GSM780719Untreated after 4 days (C1_2)45.035627
GSM780720Untreated after 4 days (C2_2)43.584320
GSM780721Untreated after 4 days (C3_2)40.86479
GSM780710Trastuzumab treated after 4 days (T1_1)38.63353
GSM780711Trastuzumab treated after 4 days (T2_1)41.811712
GSM780712Trastuzumab treated after 4 days (T3_1)45.131628
GSM780722Trastuzumab treated after 4 days (T1_2)42.54115
GSM780723Trastuzumab treated after 4 days (T2_2)49.404946
GSM780724Trastuzumab treated after 4 days (T3_2)43.225818
GSM780713Pertuzumab treated after 4 days (P1_1)39.27245
GSM780714Pertuzumab treated after 4 days (P2_1)43.760321
GSM780715Pertuzumab treated after 4 days (P3_1)40.86959
GSM780725Pertuzumab treated after 4 days (P1_2)42.240714
GSM780726Pertuzumab treated after 4 days (P2_2)49.994848
GSM780727Pertuzumab treated after 4 days (P3_2)44.417524
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)48.644944
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)41.416411
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)43.154718
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)42.399915
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)41.486511